<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158151">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01994993</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00048773</org_study_id>
    <secondary_id>HHSN275201000003I</secondary_id>
    <nct_id>NCT01994993</nct_id>
  </id_info>
  <brief_title>Antibiotic Safety (SCAMP)</brief_title>
  <acronym>SCAMP</acronym>
  <official_title>Antibiotic Safety in Infants With Complicated Intra-Abdominal Infections (SCAMP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Cohen-Wolkowiez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is evaluate whether it is safe or not to use various
      combination of antibiotics (ampicillin, metronidazole, clindamycin, piperacillin-tazobactam,
      gentamicin) in treating infants with complicated intra-abdominal infections
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most commonly used antibiotics in infants with complicated intra-abdominal infections
      are not labeled for use in this population because safety and efficacy data are lacking.
      This study will provide the safety information required for labeling. In addition, the
      pharmacokinetics(PK) and effectiveness data will also be collected during this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>Within 30 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with therapeutic success at Day 30 and Day 90</measure>
    <time_frame>30 days and 90 days after last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Confirmed by 1).Alive and 2).Negative bacterial blood cultures</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with feeding intolerance</measure>
    <time_frame>90 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Feeding intolerance confirmed by documentation of any feedings held for &gt;24 consecutive hours in infants being fed</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Grade 3 and/or Grade 4 Intraventricular hemorrhage (IVH)</measure>
    <time_frame>90 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Grade 3 IVH: Subependymal hemorrhage with extension into lateral ventricles with ventricular enlargement
Grade 4 IVH: Intraparenchymal hemorrhage</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with short bowel syndrome</measure>
    <time_frame>90 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Short bowel syndrome: Operative reports documenting resection of bowel, estimated bowel length, and absence/presence of the ileocecal valve.
Total parenteral nutrition for &gt;42 consecutive days after bowel resection, or a residual small bowel length of less than 25% expected for gestational age</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with intestinal perforation</measure>
    <time_frame>90 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Intestinal perforation: Radiological reports leading to the diagnosis of intestinal perforation. These include plain chest x-rays, plain abdominal x-rays, ultra-sonograms of the abdomen, contrast studies, and computed tomography scans of the abdomen and pelvis.
Operative reports documenting surgical procedures leading to the diagnosis and/or treatment of intestinal perforation. These include placement of a surgical drain, laparotomy, intestinal resection, and ostomy placement</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with intestinal stricture</measure>
    <time_frame>90 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Intestinal stricture: Radiology reports leading to the diagnosis of intestinal stricture. These include plain abdominal x-rays, upper gastrointestinal series with small bowel follow-through, contrast enema studies, and computed tomography scans of the abdomen and pelvis.
Operative reports documenting surgical procedures leading to the diagnosis and/or treatment of intestinal stricture. These procedures include endoscopy, laparotomy, stricture dilatation, intestinal resection, and ostomy placement</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants progressed to a higher stage of necrotizing enterocolitis (NEC)</measure>
    <time_frame>90 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Progression is determined by the clinical NEC scoring</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with gastrointestinal surgeries</measure>
    <time_frame>90 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determined by medical history and confirmed with hospital records.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Complicated Intra Abdominal Infections</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ampicillin and gentamycin and metronidazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ampicillin and gentamicin and clindamycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>piperacillin-tazobactam and gentamicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Per standard of care antibiotics, and Metronidazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ampicillin and metronidazole and gentamicin</intervention_name>
    <description>IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ampicillin and gentamicin and clindamycin</intervention_name>
    <description>IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gentamicin and Piperacillin- tazobactam</intervention_name>
    <description>IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of care antibiotics and metronidazole</intervention_name>
    <description>IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent from parent(s) or legal guardian(s)

          2. ≤32 weeks gestation at birth (Groups 1-3)

          3. ≥34 weeks gestation at birth (Group 4)

          4. PNA &lt;121 days

          5. Sufficient venous access to permit administration of study drug intravenous [IV])

          6. Presenting physical, radiological, and/or bacteriological findings of a complicated
             intra-abdominal infection within 48 hours prior to the first dose of study drug.
             Complicated intra-abdominal infections include secondary peritonitis, NEC grade II or
             higher by Bell's criteria, Hirschsprung's disease with perforation, spontaneous
             intestinal perforation, meconium ileus with perforation, bowel obstruction with
             perforation, gastroschisis with necrosis and/or perforation, omphalocele with
             necrosis and/or perforation, neonatal appendicitis, intestinal pneumatosis or portal
             venous gas,  free peritoneal air on abdominal radiographic examination, or abdominal
             abscess.

        Exclusion Criteria:

          1. History of anaphylaxis in response to study drugs

          2. Serum creatinine &gt;2 mg/dL within 48 hours prior to first dose of study drug

          3. Known alanine aminotransferase (ALT) &gt;250 U/L or aspartate aminotransferase(AST) &gt;500
             U/L on measurement closest to the time of first dose of study drug

          4. Any condition that, in the judgment of the investigator, precludes participation
             because it could affect participant safety
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Micheal Cohen-Wolkowiez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Cohen-Wolkowiez, M.D, PhD</last_name>
    <email>michael.cohenwolkowiez@dm.duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamie Gao</last_name>
    <email>jamie.gao@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire Roane, RN</last_name>
      <phone>205-934-0095</phone>
    </contact>
    <investigator>
      <last_name>Reed Dimmitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Enriquez</last_name>
      <phone>714-509-4791</phone>
    </contact>
    <investigator>
      <last_name>Antonio Arrieta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bethany Ball</last_name>
      <phone>650-725-8342</phone>
    </contact>
    <investigator>
      <last_name>Krisa Van Meurs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Mary Birch</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deborah Petruzzelli, RN</last_name>
      <phone>858-939-4891</phone>
    </contact>
    <investigator>
      <last_name>Anup Katheria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Childrens Hospital and Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ellen Knodel</last_name>
      <phone>858-966-7483</phone>
    </contact>
    <investigator>
      <last_name>Mark Speziale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Jacksonville Healthcare, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Prince, RN</last_name>
      <phone>904-244-3866</phone>
    </contact>
    <investigator>
      <last_name>Mark Hudak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shands Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Prince, RN</last_name>
      <phone>904-244-3866</phone>
    </contact>
    <investigator>
      <last_name>Mark Hudak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Navarrete, MD</last_name>
      <phone>305-585-6408</phone>
    </contact>
    <investigator>
      <last_name>Cristina Navarrete, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Children's Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Spearman, MD</last_name>
      <phone>404-785-1999</phone>
    </contact>
    <investigator>
      <last_name>Paul Spearman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Micah Tong</last_name>
      <phone>808-983-6427</phone>
    </contact>
    <investigator>
      <last_name>Venkataraman Balaraman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Smiley, RN</last_name>
      <phone>317-278-7364</phone>
    </contact>
    <investigator>
      <last_name>Brenda Poindexter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wesley Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Delmore, RN</last_name>
      <phone>316-962-8555</phone>
    </contact>
    <investigator>
      <last_name>Barry Bloom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisana State University Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Latiolais</last_name>
      <phone>318-675-5078</phone>
    </contact>
    <investigator>
      <last_name>John Vanchiere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donna Cannonier, RN</last_name>
      <phone>410-328-2438</phone>
    </contact>
    <investigator>
      <last_name>Susan Mendley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Fairview University Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Pat Osborne, RN</last_name>
      <phone>1-612-624-0581</phone>
    </contact>
    <investigator>
      <last_name>Catherine Bendel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Ellen Riordan</last_name>
      <phone>551-996-8126</phone>
    </contact>
    <investigator>
      <last_name>Rakesh Chhabra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Hospital</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erika Fernandez, MD</last_name>
      <phone>505-272-0180</phone>
    </contact>
    <investigator>
      <last_name>Erika Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brookdale University Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chika Iwuchukwu</last_name>
      <phone>718-240-5668</phone>
    </contact>
    <investigator>
      <last_name>Roger Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings County Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gratias Mundakel, MD</last_name>
      <phone>718-844-9839</phone>
    </contact>
    <investigator>
      <last_name>Gratias Mundakel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rudolph Parris</last_name>
      <phone>718-270-4657</phone>
    </contact>
    <investigator>
      <last_name>Gloria Valencia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Neonatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marilyn Weindler</last_name>
      <phone>212-305-3677</phone>
    </contact>
    <investigator>
      <last_name>Marianne Garland, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nagamah Deygoo</last_name>
      <phone>212-263-5680</phone>
    </contact>
    <investigator>
      <last_name>William Borkowsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janice Bernhardt, RN</last_name>
      <phone>919-843-2373</phone>
    </contact>
    <investigator>
      <last_name>Matthew Laughon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Reeves</last_name>
      <phone>704-347-4051</phone>
    </contact>
    <investigator>
      <last_name>Matthew Saxonhouse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberley Fisher, Pharm.D</last_name>
      <phone>919-681-4913</phone>
    </contact>
    <investigator>
      <last_name>C. Michael Cotten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sherry Moseley</last_name>
      <phone>252-744-5368</phone>
    </contact>
    <investigator>
      <last_name>Scott MacGilvray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WakeMed Faculty Neonatology</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ginger Rhodes-Ryan</last_name>
      <phone>919-350-7026</phone>
    </contact>
    <investigator>
      <last_name>James Perciaccante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Warden</last_name>
      <phone>336-718-3091</phone>
    </contact>
    <investigator>
      <last_name>Laura Downey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judy Ohlinger, RN</last_name>
      <phone>330-543-3193</phone>
    </contact>
    <investigator>
      <last_name>Michael Reed, Pharm.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Goldstein, MD</last_name>
      <phone>513-803-3294</phone>
    </contact>
    <investigator>
      <last_name>Stuart Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sue Bergant</last_name>
      <phone>216-844-5112</phone>
    </contact>
    <investigator>
      <last_name>Andrea Trembath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Womens and Infant Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jane Chandley</last_name>
      <phone>401-274-1122</phone>
    </contact>
    <investigator>
      <last_name>Joseph Bliss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Atz, MD</last_name>
      <phone>843-792-0080</phone>
    </contact>
    <investigator>
      <last_name>Andrew Atz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Steele</last_name>
      <phone>615-322-0299</phone>
    </contact>
    <investigator>
      <last_name>Jorn-Hendrik Weitkamp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelia Riley</last_name>
      <phone>214-456-8072</phone>
    </contact>
    <investigator>
      <last_name>James Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch/Inside Delivery</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristin Pollock, RN</last_name>
      <phone>409-772-5278</phone>
    </contact>
    <investigator>
      <last_name>Karen Shattuck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Aguilera</last_name>
      <phone>713-500-5522</phone>
    </contact>
    <investigator>
      <last_name>Gloria Heresi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cindy Spencer</last_name>
      <phone>801-662-4123</phone>
    </contact>
    <investigator>
      <last_name>Erin Zinkhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Blackman, RN</last_name>
      <phone>434-982-0263</phone>
    </contact>
    <investigator>
      <last_name>David Kaufman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carilion Roanoke Memorial Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pradeep Siwach</last_name>
      <phone>540-266-6012</phone>
    </contact>
    <investigator>
      <last_name>Shawn Safford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University Medical Center</investigator_affiliation>
    <investigator_full_name>Michael Cohen-Wolkowiez</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Antibiotics</keyword>
  <keyword>ampicillin</keyword>
  <keyword>metronidazole</keyword>
  <keyword>clindamycin</keyword>
  <keyword>piperacillin-tazobactam</keyword>
  <keyword>Safety</keyword>
  <keyword>Infants</keyword>
  <keyword>Intra abdominal infections</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin-2-phosphate</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Piperacillin-tazobactam combination product</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
